MOLECULAR AND IMMUNE INTERDICTION OF AIDS

位于美国艾滋病最严重的震中， 阿尔伯特·爱因斯坦医学院的医生和研究人员 (AECOM)是第一批在临床上对抗这种疾病的人之一 研究和基础研究水平。AECOM的主要优势在于 基于其高度互动的研究历史，导致了 将在实验室获得的研究结果翻译成决议 临床问题。AECOM的CFAR吸引了调查人员 国内和国际声誉，包括四名 美国国家科学院。我们由NIAID资助的艾滋病研究基地 由10项拨款组成，总额为3,391,795元，以支持有关 艾滋病毒感染的流行病学、免疫学和治疗。我们打算 继续支持互动式、协作性的广泛研究 由越来越多的研究人员在多个临床和 以预防和治疗为重点的科学学科 爱滋病模式。我们现在处于有利地位，可以提高我们的效率。 通过改善基础设施，包括：(1)新的7000平方英尺 具有集中数据管理和专用CFAR的管理核心 会议室；(2)用最新技术扩展现有核心 以其他方式可能无法获得；(3)新的生物危害核心 适应更广泛的研究学科：P3病毒学、SCID- HU/PCR和免疫学/疫苗核心。所有内核的利用率都很高 多名调查人员，并持续进行研究并激发了新的 风险投资；(4)CFAR发展基金的前两个接受者 获得了艾滋病赠款，并为CFAR带来了新的关键专业知识； (5)AECOM CFAR获得了研究界的认可和 通过广大社区，创造相互信任和 促进临床和基础研究的合作；(6)财政 CFAR的稳定性通过按存储容量使用计费系统和 通过当地的筹款。促进了广泛的互动 CFAR取得了突破，如果没有 CFAR基础设施。人工合成已经取得了令人振奋的结果 首次引起粘膜和全身感染的艾滋病疫苗 人类志愿者的体液和细胞免疫反应。 来自基础科学和临床核心的基础设施支持 AECOM CFAR将是成功完成预防性和 治疗性疫苗的开发。

Situated in the midst of the worst epicenter of AIDS in the U.S., physicians and researchers at the Albert Einstein College of Medicine (AECOM) were one of the first to confront this disease at the clinical research and basic research level. The major strength at AECOM rests upon its history of highly interactive research resulting in the translation of findings obtained in the laboratory into resolution of clinical problems. The CFAR at AECOM has attracted investigators with national and international reputations, including four members of the National Academy of Sciences. Our NIAID funded AIDS Research Base consists of 10 grants at a total of $3,391,795, supporting research on the epidemiology, immunology and treatment of HIV infection. We intend to continue to support interactive, collaborative broad-based research by an increasing number of investigators in multiple clinical and scientific disciplines with a major focus on preventive and therapeutic AIDS modalities. We are now well positioned to enhance our effectiveness through an improved infrastructure including: (1) A new 7000 sq ft administrative core with centralized data management and a CFAR dedicated conference room; (2) Expanded existing core with the latest technology that may not otherwise be obtainable; (3) New biohazard cores to accommodate a broader range of research disciplines: P3 virology, SCID- hu/PCR, and Immunology/Vaccine cores. All cores are heavily utilized by multiple investigators and have sustained research and stimulated new ventures; (4) The two previous recipients of CFAR developmental funds obtained AIDS grants and have brought to the CFAR new critical expertise; (5) The AECOM CFAR has gained recognition by the research community and by the community-at-large, creating a climate of mutual trust and collaboration to foster clinical and basic research; (6) The fiscal stability of the CFAR has been secured through the Charge-Back System and through local fundraising. The broad based interactions fostered by the CFAR yielded breakthroughs that would have been unthinkable without the CFAR infrastructure. Promising results have been obtained with synthetic AIDS vaccines which for the first time induced both mucosal and systemic humoral and cellular immune responses in human volunteers. Infrastructure support from the basic science and clinical cores of the AECOM CFAR will be crucial in the successful completion of preventive and therapeutic vaccine development.